288 related articles for article (PubMed ID: 36255682)
21. Antibodies to GM1(NeuGc) in Guillain-Barré syndrome after ganglioside therapy.
Odaka M; Yuki N; Nobile-Orazio E; Carpo M; Hirata K
J Neurol Sci; 2000 Apr; 175(2):96-106. PubMed ID: 10831769
[TBL] [Abstract][Full Text] [Related]
22. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid.
Kakio A; Nishimoto S; Yanagisawa K; Kozutsumi Y; Matsuzaki K
Biochemistry; 2002 Jun; 41(23):7385-90. PubMed ID: 12044171
[TBL] [Abstract][Full Text] [Related]
23. Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
Wu G; Lu ZH; Seo JH; Alselehdar SK; DeFrees S; Ledeen RW
Exp Neurol; 2020 Jul; 329():113284. PubMed ID: 32165255
[TBL] [Abstract][Full Text] [Related]
24. Gangliosides, α-Synuclein, and Parkinson's Disease.
Ledeen RW; Wu G
Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
[TBL] [Abstract][Full Text] [Related]
25. Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging.
Blennow K; Davidsson P; Wallin A; Fredman P; Gottfries CG; Månsson JE; Svennerholm L
Aging (Milano); 1992 Dec; 4(4):301-6. PubMed ID: 1294245
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with Abeta(1-40) peptide in a membrane mimic environment.
Mandal PK; Pettegrew JW
Neurochem Res; 2004 Feb; 29(2):447-53. PubMed ID: 15002743
[TBL] [Abstract][Full Text] [Related]
27. GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.
Chiricozzi E; Lunghi G; Di Biase E; Fazzari M; Sonnino S; Mauri L
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013258
[TBL] [Abstract][Full Text] [Related]
28. Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis.
Gross AL; Gray-Edwards HL; Bebout CN; Ta NL; Nielsen K; Brunson BL; Lopez Mercado KR; Osterhoudt DE; Batista AR; Maitland S; Seyfried TN; Sena-Esteves M; Martin DR
Brain; 2022 Apr; 145(2):655-669. PubMed ID: 34410345
[TBL] [Abstract][Full Text] [Related]
29. GM1 and GM2 gangliosides: recent developments.
Bisel B; Pavone FS; Calamai M
Biomol Concepts; 2014 Mar; 5(1):87-93. PubMed ID: 25372744
[TBL] [Abstract][Full Text] [Related]
30. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
[TBL] [Abstract][Full Text] [Related]
31. Distribution of mono-, di- and trisialo gangliosides in the brain of Actinopterygian fishes.
Viljetić B; Labak I; Majić S; Stambuk A; Heffer M
Biochim Biophys Acta; 2012 Sep; 1820(9):1437-43. PubMed ID: 22206893
[TBL] [Abstract][Full Text] [Related]
32. Human brain gangliosides in development, aging and disease.
Kracun I; Rosner H; Drnovsek V; Heffer-Lauc M; Cosović C; Lauc G
Int J Dev Biol; 1991 Sep; 35(3):289-95. PubMed ID: 1814411
[TBL] [Abstract][Full Text] [Related]
33. Age-related changes in GM1, GD1a, GT1b components of gangliosides in Wistar albino rats.
Aydin M; Cengiz S; Agaçhan B; Yilmaz H; Isbir T
Cell Biochem Funct; 2000 Mar; 18(1):41-5. PubMed ID: 10686582
[TBL] [Abstract][Full Text] [Related]
34. Isolated bovine spinal motoneurons have specific ganglioside antigens recognized by sera from patients with motor neuron disease and motor neuropathy.
Yoshino H; Miyatani N; Saito M; Ariga T; Lugaresi A; Latov N; Kushi Y; Kasama T; Yu RK
J Neurochem; 1992 Nov; 59(5):1684-91. PubMed ID: 1383424
[TBL] [Abstract][Full Text] [Related]
35. Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives.
Fusco M; Vantini G; Schiavo N; Zanotti A; Zanoni R; Facci L; Skaper SD
Ann N Y Acad Sci; 1993 Sep; 695():314-7. PubMed ID: 8239303
[TBL] [Abstract][Full Text] [Related]
36. GM1 Ganglioside: Past Studies and Future Potential.
Aureli M; Mauri L; Ciampa MG; Prinetti A; Toffano G; Secchieri C; Sonnino S
Mol Neurobiol; 2016 Apr; 53(3):1824-1842. PubMed ID: 25762012
[TBL] [Abstract][Full Text] [Related]
37. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease is associated with disordered localization of ganglioside GM1 molecular species in the human dentate gyrus.
Hirano-Sakamaki W; Sugiyama E; Hayasaka T; Ravid R; Setou M; Taki T
FEBS Lett; 2015 Nov; 589(23):3611-6. PubMed ID: 26484596
[TBL] [Abstract][Full Text] [Related]
39. Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
Alpaugh M; Galleguillos D; Forero J; Morales LC; Lackey SW; Kar P; Di Pardo A; Holt A; Kerr BJ; Todd KG; Baker GB; Fouad K; Sipione S
EMBO Mol Med; 2017 Nov; 9(11):1537-1557. PubMed ID: 28993428
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B.
Mirkin BL; Clark SH; Zhang C
Cell Prolif; 2002 Apr; 35(2):105-15. PubMed ID: 11952645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
